Amir Weiss - 09 Nov 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
12 Nov 2026, 16:10:18 UTC
Prior SEC filing
25 Aug 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Filing notes and source

Key filing fact

Amir Weiss filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 12 Nov 2026.

Key facts

  • This page summarizes Amir Weiss's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
  • 5 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:10.

Change

  • Previous filing in this sequence was filed on 25 Aug 2026.
  • Current net transaction value: -$744,049.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001897057 Primary reporting owner

Weiss Amir

Relationship
Chief Accounting Officer
Address
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares
+7,755
Change %
+59%
Price
$34.70*
Shares after
20,826
Date
09 Nov 2026
Ownership
Direct
TEVA transaction

Ordinary Shares

Sale

Transaction value
-$28,565
Shares
-662
Change %
-3.2%
Price
$43.15
Shares after
20,164
Date
09 Nov 2026
Ownership
Direct
TEVA transaction

Ordinary Shares

Sale

Transaction value
-$305,247
Shares
-7,093
Change %
-35%
Price
$43.03
Shares after
13,071
Date
09 Nov 2026
Ownership
Direct
Footnotes
F1
TEVA transaction

Ordinary Shares

Sale

Transaction value
-$410,238
Shares
-9,534
Change %
-73%
Price
$43.03
Shares after
3,537
Date
09 Nov 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value
Shares
-7,755
Change %
-100%
Price
$0.000000*
Shares after
0
Date
09 Nov 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
7,755
Exercise price
$34.70
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.02 to $43.05, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.025 to $43.04, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Stock options were granted on March 3, 2017, with 1,938 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,941 vested on March 3, 2021.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .